No Data
No Data
Poseida Gets Regenerative Medicine Advanced Therapy Designation for Myeloma Treatment; Shares Rise
Express News | Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics to Present New Clinical Data From Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients With Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Express News | Poseida Therapeutics Inc - Initiates P-BCMA-ALLO1 Phase 1B Clinical Trial in Patients With Multiple Myeloma, Generating $20 Mln Payment From Roche
Express News | Poseida Therapeutics to Present New Clinical Data From Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients With Relapsed/Refractory Multiple Myeloma at 21ST International Myeloma Society Annual Meeting